While statins show moderate promise for colorectal cancer (CRC) chemoprevention, especially in subtypes characterized by SMAD4 positivity, APC mutations, or KRAS-driven pathways, the evidence is not yet sufficient to recommend their clinical use. The gene discussed is KRAS; the disease is colorectal cancer.